{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:24:57Z","timestamp":1792189497793,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004330","name":"Smoking Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.xphs.2017.04.046","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T03:02:31Z","timestamp":1493953351000},"page":"2483-2490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1\/SLCO2A1"],"prefix":"10.1016","volume":"106","author":[{"given":"Shunsuke","family":"Kamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Aotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Gose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2017.04.046_bib1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.7754369","article-title":"Identification and characterization of a prostaglandin transporter","volume":"268","author":"Kanai","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.xphs.2017.04.046_bib2","doi-asserted-by":"crossref","first-page":"28424","DOI":"10.1074\/jbc.M408286200","article-title":"Prostaglandin signaling in the renal collecting duct: release, reuptake, and oxidation in the same cell","volume":"280","author":"Nomura","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xphs.2017.04.046_bib3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.109.862946","article-title":"Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice","volume":"121","author":"Chang","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.xphs.2017.04.046_bib4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/humu.22042","article-title":"Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing","volume":"33","author":"Seifert","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.xphs.2017.04.046_bib5","doi-asserted-by":"crossref","first-page":"e1005581","DOI":"10.1371\/journal.pgen.1005581","article-title":"A\u00a0hereditary enteropathy caused by mutations in the SLCO2A1 gene, encoding a prostaglandin transporter","volume":"11","author":"Umeno","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.xphs.2017.04.046_bib6","doi-asserted-by":"crossref","first-page":"e0123895","DOI":"10.1371\/journal.pone.0123895","article-title":"Prostaglandin transporter (PGT\/SLCO2A1) protects the lung from bleomycin-induced fibrosis","volume":"10","author":"Nakanishi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xphs.2017.04.046_bib7","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1124\/jpet.105.091975","article-title":"Identification of a new class of prostaglandin transporter inhibitors and characterization of their biological effects on prostaglandin E2 transport","volume":"316","author":"Chi","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.xphs.2017.04.046_bib8","doi-asserted-by":"crossref","first-page":"e0131735","DOI":"10.1371\/journal.pone.0131735","article-title":"Inhibition of the prostaglandin transporter PGT lowers blood pressure in hypertensive rats and mice","volume":"10","author":"Chi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xphs.2017.04.046_bib9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ajpath.2012.03.012","article-title":"Prostaglandin transporter modulates wound healing in diabetes by regulating prostaglandin-induced angiogenesis","volume":"181","author":"Syeda","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.xphs.2017.04.046_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.bcp.2015.10.009","article-title":"OATP2A1\/SLCO2A1-mediated prostaglandin E loading into intracellular acidic compartments of macrophages contributes to exocytotic secretion","volume":"98","author":"Shimada","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.xphs.2017.04.046_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/jpet.109.154518","article-title":"Influence of cyclooxygenase inhibitors on the function of the prostaglandin transporter organic anion-transporting polypeptide 2A1 expressed in human gastroduodenal mucosa","volume":"332","author":"Mandery","year":"2010","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.xphs.2017.04.046_bib12","unstructured":"Suzuki Y, Ohta K, Inoue K, Yuasa H. A rapid assay method for the assessment of the functionality of organic anion transporting polypeptide 2A1 by using a fluorescent substrate. The 135th Annual Meeting of the Pharmaceutical Society of Japan in Kobe, 03\/27 2015, pp. 27S-pm10."},{"key":"10.1016\/j.xphs.2017.04.046_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.prostaglandins.2015.12.003","article-title":"Prostaglandin transporter (OATP2A1\/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE","volume":"122","author":"Gose","year":"2016","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.xphs.2017.04.046_bib14","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1002\/jps.24462","article-title":"Kinetic evaluation of determinant factors for cellular accumulation of protoporphyrin IX induced by external 5-aminolevulinic acid for photodynamic cancer therapy","volume":"104","author":"Nakanishi","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2017.04.046_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xphs.2017.04.046_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/mp400513k","article-title":"Mathematical modeling of the in\u00a0vitro hepatic disposition of mycophenolic acid and its glucuronide in sandwich-cultured human hepatocytes","volume":"11","author":"Matsunaga","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2017.04.046_bib17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0022-3565(24)38187-X","article-title":"Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells","volume":"289","author":"Yamazaki","year":"1999","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.xphs.2017.04.046_bib18","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A\u00a0pharmacokinetic analysis program (multi) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J\u00a0Pharmacobiodyn"},{"key":"10.1016\/j.xphs.2017.04.046_bib19","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1073\/pnas.1033060100","article-title":"The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs","volume":"100","author":"Reid","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xphs.2017.04.046_bib20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.165.3.1605","article-title":"Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors","volume":"165","author":"Penglis","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xphs.2017.04.046_bib21","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/ph3051530","article-title":"Nonsteroidal anti-inflammatory drugs (NSAIDs): progress in small molecule drug development","volume":"3","author":"Rao","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.xphs.2017.04.046_bib22","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1074\/jbc.273.12.6689","article-title":"Mechanism of prostaglandin E2 transport across the plasma membrane of HeLa cells and Xenopus oocytes expressing the prostaglandin transporter \u201cPGT.\u201d","volume":"273","author":"Chan","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xphs.2017.04.046_bib23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1124\/jpet.111.181354","article-title":"Development of a high-affinity inhibitor of the prostaglandin transporter","volume":"339","author":"Chi","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.xphs.2017.04.046_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0031-6997(24)01482-0","article-title":"International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits","volume":"53","author":"Khakh","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.xphs.2017.04.046_bib25","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1038\/emboj.2010.126","article-title":"P2X4 receptors mediate PGE2 release by tissue-resident macrophages and initiate inflammatory pain","volume":"29","author":"Ulmann","year":"2010","journal-title":"EMBO J"},{"key":"10.1016\/j.xphs.2017.04.046_bib26","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1096\/fj.12-205765","article-title":"P2X7 receptor-stimulation causes fever via PGE2 and IL-1beta release","volume":"26","author":"Barbera-Cremades","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.xphs.2017.04.046_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0166-6851(99)00204-2","article-title":"Comparative study of Leishmania mexicana and Trypanosoma brucei NAD-dependent glycerol-3-phosphate dehydrogenase","volume":"106","author":"Marche","year":"2000","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.xphs.2017.04.046_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/j.1552-4604.1986.tb02897.x","article-title":"Clinical pharmacokinetics of suramin in patients with HTLV-III\/LAV infection","volume":"26","author":"Collins","year":"1986","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2017.04.046_bib29","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1124\/dmd.116.069468","article-title":"Cysteinyl leukotriene receptor 1\/2 antagonists nonselectively modulate organic anion transport by multidrug resistance proteins (MRP1-4)","volume":"44","author":"Csandl","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2017.04.046_bib30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/bmc.983","article-title":"Development and validation of a sensitive LC-MS\/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study","volume":"22","author":"Bharathi","year":"2008","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.xphs.2017.04.046_bib31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00228-010-0908-0","article-title":"The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast","volume":"67","author":"Karonen","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2017.04.046_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1046\/j.1365-2125.1997.00650.x","article-title":"Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers","volume":"44","author":"Brocks","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2017.04.046_bib33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003495-200161020-00012","article-title":"Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma","volume":"61","author":"Dunn","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.xphs.2017.04.046_bib34","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/00003495-200363100-00005","article-title":"Pranlukast: a review of its use in the management of asthma","volume":"63","author":"Keam","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.xphs.2017.04.046_bib35","doi-asserted-by":"crossref","first-page":"11892","DOI":"10.1074\/jbc.M109.072629","article-title":"Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine","volume":"285","author":"Ishizuka","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xphs.2017.04.046_bib36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/00912700122010393","article-title":"Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects","volume":"41","author":"Schwocho","year":"2001","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2017.04.046_bib37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0009-9236(95)90020-9","article-title":"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans","volume":"58","author":"Lo","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2017.04.046_bib38","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/pr.112.007278","article-title":"A\u00a0systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists","volume":"65","author":"Michel","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.xphs.2017.04.046_bib39","doi-asserted-by":"crossref","first-page":"F1097","DOI":"10.1152\/ajprenal.00151.2001","article-title":"Identification of lactate as a driving force for prostanoid transport by prostaglandin transporter PGT","volume":"282","author":"Chan","year":"2002","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917303155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917303155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:50:26Z","timestamp":1750225826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354917303155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0022354917303155"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2017.04.046","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1\/SLCO2A1","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2017.04.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}